This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
bacteria:t3e:xopai [2024/12/16 14:38] – [The Type III Effector XopAI from //Xanthomonas//] rkoebnik | bacteria:t3e:xopai [2025/07/13 23:25] (current) – jfpothier | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== The Type III Effector XopAI from // | ====== The Type III Effector XopAI from // | ||
- | Author: [[https:// | + | Author: [[https:// |
Class: XopAI\\ | Class: XopAI\\ | ||
Line 16: | Line 16: | ||
Based on the complete genome sequence, XopAI (XAC3230) was proposed as a Hrp regulon candidate (da Silva //et al.//, 2002). | Based on the complete genome sequence, XopAI (XAC3230) was proposed as a Hrp regulon candidate (da Silva //et al.//, 2002). | ||
- | Co-regulation of //xopAI// with other HrpG-controlled genes was also proposed by Noël //et al.// (2006) based on the observation that 200 bp of the 5' sequence including promoter and coding regions of //xopE2// (// | + | Co-regulation of //xopAI// with other HrpG-controlled genes was also proposed by Noël //et al.// (2006) based on the observation that 200 bp of the 5' sequence including promoter and coding regions of //xopE2// (// |
Based on homology to effectors from // | Based on homology to effectors from // | ||
+ | |||
=== (Experimental) evidence for being a T3E === | === (Experimental) evidence for being a T3E === | ||
Line 25: | Line 26: | ||
=== Regulation === | === Regulation === | ||
- | Using microarrays, | + | Using microarrays, |
=== Phenotypes === | === Phenotypes === | ||
Line 33: | Line 35: | ||
The XopAI N‐terminal domain contains a myristoylation motif, which was previously identified in several T3Es of //P. syringae//, indicating that effectors with this N‐terminal domain are targeted to host cellular membranes (White //et al.//, 2009). | The XopAI N‐terminal domain contains a myristoylation motif, which was previously identified in several T3Es of //P. syringae//, indicating that effectors with this N‐terminal domain are targeted to host cellular membranes (White //et al.//, 2009). | ||
+ | |||
=== Enzymatic function === | === Enzymatic function === | ||
Line 40: | Line 43: | ||
Structural homologs of XopAI are, among others, the HopU1 (// | Structural homologs of XopAI are, among others, the HopU1 (// | ||
+ | |||
=== Interaction partners === | === Interaction partners === | ||
Line 46: | Line 50: | ||
=== In xanthomonads === | === In xanthomonads === | ||
- | XopAI is conserved in the Citrus canker strains, including //X. citri// pv. //citri// and //X. citri// pv. // | + | XopAI is conserved in the Citrus canker strains, including //X. citri// pv. //citri// and //X. citri// pv. // |
+ | |||
+ | XopAI homologs were also found in //X. citri// pv. //bilvae// and //X. citri// pv. // | ||
- | XopAI homologs were also found in //X. citri// pv. //bilvae// and //X. citri// pv. // | ||
=== In other plant pathogens/ | === In other plant pathogens/ | ||
Line 75: | Line 80: | ||
White FF, Potnis N, Jones JB, Koebnik R (2009). The type III effectors of // | White FF, Potnis N, Jones JB, Koebnik R (2009). The type III effectors of // | ||
+ | |||
+ | ===== Acknowledgements ===== | ||
+ | |||
+ | This fact sheet is based upon work from COST Action CA16107 EuroXanth, supported by COST (European Cooperation in Science and Technology). | ||
+ | |||